ViroPharma disclosed that on April 13 the company filed a complaint for declaratory and injunctive relief with the United States District Court for the District of Columbia against the Food and Drug Administration and the United States Department of Health and Human Services. The complaint seeks review under the Administrative Procedure Act of the FDA’s response to ViroPharma’s petition for stay of action and the FDA’s approval of three Abbreviated New Drug Applications for generic versions of ViroPharma’s Vancocin capsules. Concurrently with the filing of the complaint, ViroPharma filed a motion for a temporary restraining order and/or a preliminary injunction. On April 23, the District Court denied ViroPharma’s motion. ViroPharma said it is evaluating potential legal options.